DOJ Schedule III cannabis order creates uncertainty for D.C.’s medical self-certification program
The Justice Department’s move to classify state-licensed medical cannabis as Schedule III is creating uncertainty for Washington, D.C.’s self-certification system, which allows patients to access cannabis without a physician’s approval, because the federal order requires certifications to be issued by a practitioner and may directly conflict with the District’s current framework. As regulators and stakeholders await further guidance, the mismatch between federal requirements and local policy could force changes to the program or disrupt patient access in the near term.
- The next ABC Board meeting is April 29, 2026: watch, agenda.
- Catch up on the April 22 disposition.
- March metric sales.
Virginia lawmakers reject governor’s changes, leaving cannabis bill in limbo
Virginia lawmakers reconvened to reject Gov. Abigail Spanberger’s proposed amendments to several high-profile bills—including cannabis sales, labor, gun policy, and prescription drug affordability—highlighting growing tensions within the state’s Democratic leadership. By refusing the changes, legislators sent the original measures back to the governor, leaving the future of the state’s adult-use cannabis market and other key policies uncertain as she now decides whether to sign, veto, or let them become law.
Sudden federal cannabis shift leaves Maryland regulators scrambling for clarity
A sudden federal move to reclassify medical cannabis as a Schedule III drug has created confusion among Maryland regulators and industry operators, with little guidance on how the change should be implemented at the state level. Officials and businesses are now grappling with how the shift affects existing rules, patient access, and compliance, raising concerns about regulatory gaps and potential disruptions to the state’s cannabis program.
- The Maryland Cannabis Administration said in a statement that the federal rescheduling order does not change state law or immediately affect patient access or business operations, and regulators are still reviewing the action with legal counsel before issuing guidance.
ICYMI: D.C. operator files $1.6M lawsuit as Virginia delays and market tensions rise
East Coast Roundup
Connecticut is advancing limits on THC potency in cannabis products, reflecting growing regulatory efforts to curb high-strength formulations in the state market.
Pennsylvania’s cannabis legalization debate includes discussion of a “clean slate” provision that would expand criminal record relief for past cannabis-related offenses alongside potential reform.
Massachusetts is weighing updates to its cannabis laws that could impact the structure and operation of both recreational and medical marijuana retailers statewide.
Culture & More
A CNN health report examines concerns from experts about rising cannabis potency and its potential implications for consumer health and wellness outcomes.
Some cannabis magazines are being restricted or excluded from dispensaries because retailers are tightening content standards and avoiding material they view as too explicit, controversial, or misaligned with brand-safe retail environments.
Around the Country
Colorado stakeholders are assessing how federal marijuana rescheduling could reshape business operations, taxation, and cannabis-related scientific research.
Authorities in Alameda County, California dismantled three suspected illegal cannabis grow operations, seizing about 20,000 cannabis plants in a major enforcement action.
Berkeley, California is expanding youth-focused alternatives and programs aimed at reducing cannabis use and providing prevention and support services.
From the swamp
Advocacy groups argue that federal cannabis rescheduling does not provide legal relief for people with prior cannabis convictions and are urging broader presidential clemency or expungement action to address past enforcement harms.
Cannabis companies are responding positively in markets and litigation strategy following the U.S. federal government’s move to reclassify cannabis as a less dangerous drug under Schedule III.
